Gilead Sciences, Inc.

Selcia Limited

Cypralis Limited

Gilead Pharmasset LLC

Leland Stanford Junior University

Adam James Schrier

Dustin S Siegel

Kapil Kumar Karki

Petr Jansa

Michael Sangi

James G Taylor

Hyung-Jung Pyun

Richard L Mackman

Linos Lazarides

Victoria Alexandra Steadman

Andrew John Keats

Karine G Poullennec

Caroline Aciro

David Kenneth Dean

Darryl Kato

Adrian John Highton

Jeff A Zablocki

John O Link

Zheng-Yu Yang

Sheila M Zipfel

Eda Y Canales

Simon Neil Pettit

Ashley Anne Katana

Ruben Martinez

Neil Andrew Dunbar

Randall W Vivian

Jean Yves Chiva

Jeromy J Cottell

Barton W Phillips

Chinh Viet Tran

Tetsuya Kobayashi

Teresa Alejandra Trejo Martin

Kyla Bjornson

Laurent P Debien

Gregory Notte

Kirk L Stevens

Roland D Saito

Joshua J Van Veldhuizen

Jennifer Alissa Loyer-Drew

Marina Shatskikh

William John Watkins

Kevin S Currie

Scott A Mitchell

Chandrasekar Venkataramani

Scott E Lazerwith

Peter A Blomgren

Lianhong Xu

Jeffrey E Kropf

Jennifer Anne Treiberg

Jianjun Xu

Seung H Lee

Juan A Guerrero

Rick Andrew Lee

Zhongdong Zhao

Jiayao Li

Aaron C Schmitt

Zhimin Du

Jayaraman Chandrasekhar

Stephane Perreault

Bruce Ross

Jennifer R Lo

Nathan D Shapiro

Julie Farand

Daniel H Byun

Jonathan Clive Tripp

Katie Ann Keaton

Andrew W Waltman

Denise A Colby

Troy Evan Reynolds

Johann Chan

Dominika Pcion

Lina Chan

Donald Tang

Amy Cagulada

Chris Levins

Adam Littke

Pamela Seng

Lawrence Yu

Nicholas Mai

Greg Watt

Gary Bruce Phillips

Michael L Mitchell

Paul A Wender

Richard Y Huang

Elbert Chin

Chienhung Chou

Ryan McFadden

Zhenhong R Cai

Lars V Heumann

Jin-Ming Xiong

Chao-I Hung

Prasenjit Kumar Mukherjee

Elizabeth J Mieuli

Yifan Deng

Weng K Chang

Megan K Armstrong

Sudha Kondappally

Sudha Kondapally

JinMing Xiong

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

Compounds of Formula I are disclosed  As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Inhibitors of hepatitis C virus

Provided are compounds of Formula I:  and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Macrocyclic inhibitors of flaviviridae viruses

Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Synthesis of an antiviral compound

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Syk inhibitors

[object Object]

Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.

Growing community of inventors

Redwood City, CA, United States of America

Adam James Schrier